{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:04:58Z","timestamp":1762527898859,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Hollywood Canteen Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ajoc.2020.100968","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T02:21:59Z","timestamp":1602901319000},"page":"100968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical manifestations of intravitreal bortezomib injection"],"prefix":"10.1016","volume":"20","author":[{"given":"Chan","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-487X","authenticated-orcid":false,"given":"JoAnn A.","family":"Giaconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ajoc.2020.100968_bib1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajoc.2020.100968_bib2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ajo.2010.11.017","article-title":"Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file","volume":"151","author":"Brechner","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajoc.2020.100968_bib3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/IAE.0b013e3182278ab4","article-title":"A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections","volume":"31","author":"van der Reis","year":"2011","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.ajoc.2020.100968_bib4","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ajoc.2020.100968_bib5","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1167\/iovs.06-1147","article-title":"The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro","volume":"48","author":"Poulaki","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajoc.2020.100968_bib6","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1167\/iovs.12-9505","article-title":"Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats","volume":"53","author":"Chen","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"29","key":"10.1016\/j.ajoc.2020.100968_bib7","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.2174\/092986708786848622","article-title":"Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?","volume":"15","author":"Gilardini","year":"2008","journal-title":"Curr Med Chem"},{"issue":"9","key":"10.1016\/j.ajoc.2020.100968_bib8","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Canc Res"},{"issue":"2","key":"10.1016\/j.ajoc.2020.100968_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ajo.2011.11.023","article-title":"Avastin doesn't blind people, people blind people","volume":"153","author":"Gonzalez","year":"2012","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993620302838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993620302838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:59:44Z","timestamp":1762527584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993620302838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":9,"alternative-id":["S2451993620302838"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100968","relation":{},"ISSN":["2451-9936"],"issn-type":[{"type":"print","value":"2451-9936"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical manifestations of intravitreal bortezomib injection","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100968"}}